✦ LIBER ✦

Cost-Per-Responder Analysis of Biological Agents for the Treatment of Active Ankylosing Spondylitis in Germany

✍ Scribed by Betts, K.A.; Joshi, A.D.; Yan, S.Y.; Zhou, Z.; Rao, S.; Wolff, M.; Cifaldi, M.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Assessment of Cost-Effectiveness Models

✍ Gokhale, S.; Mallya, U.; Mpofu, S. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

PMS47 The Long Term Cost-Effectiveness o

✍ J. Farrell; N. Muszbek; O. Sheppard; M. Chaudhary; H. Naci; S. Kachroo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

PMS22 ADALIMUMAB, ETANERCEPT AND INFLIXI

✍ T Macioch; M Niewada; W Wrona; D Golicki; T Hermanowski 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

Number needed to treat and cost per resp

📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Cost-effectiveness of drotrecogin alfa (

✍ Aileen R Neilson; Hilmar Burchardi; Chris Chinn; Johannes Clouth; Heinz Schneide 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 116 KB

PSS14 Cost-Effectiveness of Biologic The

✍ Betts, K.; Yan, Y.; Sundaram, M.; Hengst, N.; Wolff, M.; Bensimon, A.G. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB